30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Tectonic Therapeutic Inc (TECX)

Track

Recent insider trading at Tectonic Therapeutic Inc. shows a net sell-off over the last 90 days, with total sell value exceeding buy value. Notably, Chief Medical Officer Marcella Ruddy and Chief Scientific Officer Peter McNamara have engaged in multiple planned and proposed sales. The company's stock has seen a slight decrease in the last 90 days.
Stock chart
Ticker: TECX Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Ruddy Marcella K.
Chief Medical Officer
1 sale — total 31,950 USD
Planned sale 4 May 2026
Value US$1,426,244.14 | Price 333.05 | Shares 1,279
Planned sale 1 Apr 2026
Value US$1,205,151.34 | Price 243.29 | Shares 63,855
Planned sale 6 Mar 2026
Value US$300,000.00 | Price 30.00 | Shares 10,000
Planned sale 6 Mar 2026
Value US$7,525.00 | Price 35.00 | Shares 215
Planned sale 6 Mar 2026
Value US$181,410.00 | Price 30.00 | Shares 6,047
Proposed sale 6 Mar 2026
Value US$174,396.70 | Price 27.85 | Shares 6,262
Proposed sale 6 Mar 2026
Value US$336,010.25 | Price 27.85 | Shares 12,065
Planned sale 4 Mar 2026
Value US$41,250.00 | Price 25.00 | Shares 1,650
Proposed sale 4 Mar 2026
Value US$40,251.75 | Price 24.40 | Shares 1,650
Planned sale 3 Mar 2026
Value US$36,376.94 | Price 22.06 | Shares 1,649
Proposed sale 3 Mar 2026
Value US$37,927.00 | Price 23.00 | Shares 1,649
Buy 11 Feb 2026
Value US$52,750.00 | Price 21.10 | Shares 2,500
Buy 10 Feb 2026
Value US$129,660.00 | Price 21.61 | Shares 6,000
Buy 11 Apr 2025
Value US$875,944.86 | Price 16.31 | Shares 53,706
Buy 11 Apr 2025
Value US$154,586.18 | Price 16.31 | Shares 9,478
Buy 10 Apr 2025
Value US$767,204.34 | Price 16.73 | Shares 45,858
Buy 10 Apr 2025
Value US$135,379.16 | Price 16.73 | Shares 8,092
Buy 9 Apr 2025
Value US$73,956.88 | Price 15.23 | Shares 4,856
Buy 9 Apr 2025
Value US$237,063.30 | Price 14.62 | Shares 16,215
Buy 9 Apr 2025
Value US$13,052.11 | Price 15.23 | Shares 857
Buy 9 Apr 2025
Value US$41,827.82 | Price 14.62 | Shares 2,861
Buy 7 Apr 2025
Value US$7,053,750.00 | Price 17.10 | Shares 412,500
Buy 7 Apr 2025
Value US$1,496,250.00 | Price 17.10 | Shares 87,500
Sale 7 Apr 2025
Value US$8,550,000.00 | Price 17.10 | Shares 500,000
Buy 5 Feb 2025
Value US$33,000,000.00 | Price 50.00 | Shares 660,000
Buy 5 Feb 2025
Value US$6,999,977.16 | Price 54.14 | Shares 129,294
Buy 5 Feb 2025
Value US$249,964.38 | Price 54.14 | Shares 4,617
Buy 22 Oct 2024
Value US$10,077,000.00 | Price 33.59 | Shares 300,000
Buy 26 Sep 2024
Value US$74,088.00 | Price 30.87 | Shares 2,400
Buy 26 Sep 2024
Value US$122,507.00 | Price 30.10 | Shares 4,070
Buy 26 Sep 2024
Value US$553,440.87 | Price 29.13 | Shares 18,999
Buy 26 Sep 2024
Value US$690,792.96 | Price 28.16 | Shares 24,531
Buy 14 May 2024
Value US$385,946.60 | Price 1.30 | Shares 296,882
Buy 13 May 2024
Value US$272,226.78 | Price 1.26 | Shares 216,053
Buy 13 May 2024
Value US$313,319.50 | Price 1.24 | Shares 253,700
Proposed sale 14 Jul 2023
Value US$177,534.24 | Price 1.38 | Shares 128,648
Proposed sale 7 Jun 2023
Value US$173,373.86 | Price 1.18 | Shares 146,927
Proposed sale 5 Jun 2023
Value US$7,938.72 | Price 1.11 | Shares 7,152
Proposed sale 25 May 2023
Value US$227,946.02 | Price 1.22 | Shares 186,841
Proposed sale 24 May 2023
Value US$57,336,601.40 | Price 196.21 | Shares 292,215
Proposed sale 24 May 2023
Value US$57,336,601.40 | Price 789.72 | Shares 72,604
Proposed sale 24 May 2023
Value US$57,336,601.40 | Price 789.72 | Shares 72,604
Buy 17 Feb 2021
Value US$23,420.00 | Price 11.71 | Shares 2,000
Planned sale 12 Feb 2020
Value US$40,691.98 | Price 29.07 | Shares 1,400
Planned sale 11 Feb 2020
Value US$420,000.00 | Price 28.00 | Shares 15,000
Planned sale 11 Feb 2020
Value US$517,099.03 | Price 28.10 | Shares 18,404
Planned sale 11 Feb 2020
Value US$1,219,981.55 | Price 27.36 | Shares 44,596
Planned sale 28 Jan 2020
Value US$230,000.00 | Price 23.00 | Shares 10,000
Buy 19 Jul 2019
Value US$15,000,003.50 | Price 18.50 | Shares 810,811
Buy 19 Jul 2019
Value US$15,000,003.50 | Price 18.50 | Shares 810,811
Planned sale 8 Apr 2019
Value US$2,692.00 | Price 26.92 | Shares 100
Planned sale 8 Apr 2019
Value US$62,021.28 | Price 25.84 | Shares 2,400
Planned sale 8 Apr 2019
Value US$18,893.25 | Price 27.07 | Shares 698
Planned sale 5 Apr 2019
Value US$22,723.81 | Price 26.21 | Shares 867
Planned sale 5 Apr 2019
Value US$169,759.03 | Price 25.59 | Shares 6,633
Planned sale 5 Apr 2019
Value US$362,617.84 | Price 27.26 | Shares 13,302
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-06 2026-05-04 PlS Planned sale
Ruddy Marcella K.

Chief Medical Officer

Officer
1,279 +49.4%
333.05
US$1,426,244 		1,279 +49.4% 333.05 US$1,426,244
2026-04-03 2026-04-01 PlS Planned sale
Ruddy Marcella K.

Chief Medical Officer

Officer
63,855 +12.0%
243.29
US$1,205,151 		63,855 +12.0% 243.29 US$1,205,151
2026-03-09 2026-03-06 PlS Planned sale
Ruddy Marcella K.

Chief Medical Officer

Officer
94,583 +44.7%
143.25
US$3,844,068 		94,583 +44.7% 143.25 US$3,844,068
2026-03-09 2026-03-06 PlS Planned sale
McNamara Peter

Chief Scientific Officer

Officer
215 -0.4%
35.00
US$7,525 		215 -0.4% 35.00 US$7,525
2026-03-09 2026-03-06 PlS Planned sale
McNamara Peter

Chief Scientific Officer

Officer
6,047 -9.8%
30.00
US$181,410 		6,047 -9.8% 30.00 US$181,410
2026-03-06 2026-03-06 PrS Proposed sale
PETER MCNAMARA

Officer

Officer
6,262
27.85
US$174,397 		6,262 27.85 US$174,397
2026-03-06 2026-03-06 PrS Proposed sale
MARCELLA RUDDY

Officer

Officer
12,065
27.85
US$336,010 		12,065 27.85 US$336,010
2026-03-05 2026-03-04 PlS Planned sale
McNamara Peter

Chief Scientific Officer

Officer
1,650 -2.7%
25.00
US$41,250 		1,650 -2.7% 25.00 US$41,250
2026-03-04 2026-03-04 PrS Proposed sale
PETER MCNAMARA

Officer

Officer
1,650
24.40
US$40,252 		1,650 24.40 US$40,252
2026-03-05 2026-03-03 PlS Planned sale
McNamara Peter

Chief Scientific Officer

Officer
1,649 -4.2%
22.06
US$36,377 		1,649 -4.2% 22.06 US$36,377
2026-03-03 2026-03-03 PrS Proposed sale
PETER MCNAMARA

Officer

Officer
1,649
23.00
US$37,927 		1,649 23.00 US$37,927
2026-02-12 2026-02-11 B Purchase
3.3
REICIN ALISE

Chief Executive Officer

Executive Director
2,500 +1.1%
21.10
US$52,750 		2,500 +1.1% 21.10 US$52,750
2026-02-11 2026-02-10 B Purchase
3.3
Lochner Daniel

Chief Financial Officer

Officer
6,000 +23.0%
21.61
US$129,660 		6,000 +23.0% 21.61 US$129,660
2025-04-11 2025-04-11 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
53,706 +3.7%
16.31
US$875,945 		53,706 +3.7% 16.31 US$875,945
2025-04-11 2025-04-11 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
9,478 +0.2%
16.31
US$154,586 		9,478 +0.2% 16.31 US$154,586
2025-04-11 2025-04-10 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
45,858 +3.3%
16.73
US$767,204 		45,858 +3.3% 16.73 US$767,204
2025-04-11 2025-04-10 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
8,092 +0.2%
16.73
US$135,379 		8,092 +0.2% 16.73 US$135,379
2025-04-11 2025-04-09 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
4,856 +0.3%
15.23
US$73,957 		4,856 +0.3% 15.23 US$73,957
2025-04-11 2025-04-09 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
16,215 +1.2%
14.62
US$237,063 		16,215 +1.2% 14.62 US$237,063
2025-04-11 2025-04-09 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
857 +0.0%
15.23
US$13,052 		857 +0.0% 15.23 US$13,052
2025-04-11 2025-04-09 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
2,861 +0.1%
14.62
US$41,828 		2,861 +0.1% 14.62 US$41,828
2025-04-09 2025-04-07 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
412,500 +42.5%
17.10
US$7,053,750 		412,500 +42.5% 17.10 US$7,053,750
2025-04-09 2025-04-07 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
87,500 +2.1%
17.10
US$1,496,250 		87,500 +2.1% 17.10 US$1,496,250
2025-04-07 2025-04-07 S Sale
1.4
MCGUIRE TERRANCE
Non-Executive Director
500,000 -46.6%
17.10
US$8,550,000 		500,000 -46.6% 17.10 US$8,550,000
2025-02-07 2025-02-05 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
660,000 +212.8%
50.00
US$33,000,000 		660,000 +212.8% 50.00 US$33,000,000
2025-02-07 2025-02-05 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
129,294 +3.2%
54.14
US$6,999,977 		129,294 +3.2% 54.14 US$6,999,977
2025-02-07 2025-02-05 B Purchase
3.3
Lochner Daniel

Chief Financial Officer

Officer
4,617 +inf%
54.14
US$249,964 		4,617 +inf% 54.14 US$249,964
2024-10-24 2024-10-22 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
300,000 +7.9%
33.59
US$10,077,000 		300,000 +7.9% 33.59 US$10,077,000
2024-09-26 2024-09-26 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
2,400 +0.1%
30.87
US$74,088 		2,400 +0.1% 30.87 US$74,088
2024-09-26 2024-09-26 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
4,070 +0.1%
30.10
US$122,507 		4,070 +0.1% 30.10 US$122,507
2024-09-26 2024-09-26 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
18,999 +0.5%
29.13
US$553,441 		18,999 +0.5% 29.13 US$553,441
2024-09-26 2024-09-26 B Purchase
3.4
SPRINGER TIMOTHY A
Non-Executive Director Large shareholder
24,531 +0.7%
28.16
US$690,793 		24,531 +0.7% 28.16 US$690,793
2024-05-15 2024-05-14 B Purchase
2.9
Leonard Braden Michael
Large shareholder
296,882 +6.6%
1.30
US$385,947 		296,882 +6.6% 1.30 US$385,947
2024-05-15 2024-05-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
216,053 +5.1%
1.26
US$272,227 		216,053 +5.1% 1.26 US$272,227
2024-05-15 2024-05-13 B Purchase
2.9
Leonard Braden Michael
Large shareholder
253,700 +6.3%
1.24
US$313,320 		253,700 +6.3% 1.24 US$313,320
2023-07-14 2023-07-14 PrS Proposed sale
Petersen Deanna M

Officer

Officer
128,648
1.38
US$177,534 		128,648 1.38 US$177,534
2023-06-07 2023-06-07 PrS Proposed sale
Geoff MacKay

Former CEO
146,927
1.18
US$173,374 		146,927 1.18 US$173,374
2023-06-05 2023-06-05 PrS Proposed sale
Geoff MacKay

Former CEO
7,152
1.11
US$7,939 		7,152 1.11 US$7,939
2023-05-25 2023-05-25 PrS Proposed sale
Geoff MacKay

Former CEO
186,841
1.22
US$227,946 		186,841 1.22 US$227,946
2023-05-24 2023-05-24 PrS Proposed sale
Geoff MacKay

Former CEO
292,215
196.21
US$57,336,601 		292,215 196.21 US$57,336,601
2023-05-24 2023-05-24 PrS Proposed sale
The Mac C. MacKay Irrevocable Trust

Child of former CEO
72,604
789.72
US$57,336,601 		72,604 789.72 US$57,336,601
2023-05-24 2023-05-24 PrS Proposed sale
The Kali M MacKay Irrevocable Trust DTD 1/6/2022

Child of Former CEO
72,604
789.72
US$57,336,601 		72,604 789.72 US$57,336,601
2021-02-18 2021-02-17 B Purchase
1.3
Donenberg Phillip B.
Non-Executive Director
2,000 +inf%
11.71
US$23,420 		2,000 +inf% 11.71 US$23,420
2020-02-14 2020-02-12 PlS Planned sale
MACKAY GEOFFREY

See Remarks

Executive Director
1,400 -0.4%
29.07
US$40,692 		1,400 -0.4% 29.07 US$40,692
2020-02-11 2020-02-11 PlS Planned sale
PAIGE CHRISTOPHER
Non-Executive Director
15,000 -5.6%
28.00
US$420,000 		15,000 -5.6% 28.00 US$420,000
2020-02-11 2020-02-11 PlS Planned sale
MACKAY GEOFFREY

See Remarks

Executive Director
18,404 -5.0%
28.10
US$517,099 		18,404 -5.0% 28.10 US$517,099
2020-02-11 2020-02-11 PlS Planned sale
MACKAY GEOFFREY

See Remarks

Executive Director
44,596 -10.9%
27.36
US$1,219,982 		44,596 -10.9% 27.36 US$1,219,982
2020-01-30 2020-01-28 PlS Planned sale
PAIGE CHRISTOPHER
10,000 -3.6%
23.00
US$230,000 		10,000 -3.6% 23.00 US$230,000
2019-07-23 2019-07-19 B Purchase
3.4
Booth Bruce
810,811 +17.0%
18.50
US$15,000,004 		810,811 +17.0% 18.50 US$15,000,004
2019-07-23 2019-07-19 B Purchase
3.3
Atlas Venture Fund X, L.P.
Large shareholder
810,811 +17.0%
18.50
US$15,000,004 		810,811 +17.0% 18.50 US$15,000,004
2019-04-09 2019-04-08 PlS Planned sale
PAIGE CHRISTOPHER
100 -0.0%
26.92
US$2,692 		100 -0.0% 26.92 US$2,692
2019-04-09 2019-04-08 PlS Planned sale
PAIGE CHRISTOPHER
2,400 -0.9%
25.84
US$62,021 		2,400 -0.9% 25.84 US$62,021
2019-04-09 2019-04-08 PlS Planned sale
MACKAY GEOFFREY

See Remarks

Executive Director
698 -0.2%
27.07
US$18,893 		698 -0.2% 27.07 US$18,893
2019-04-09 2019-04-05 PlS Planned sale
PAIGE CHRISTOPHER
867 -0.3%
26.21
US$22,724 		867 -0.3% 26.21 US$22,724
2019-04-09 2019-04-05 PlS Planned sale
PAIGE CHRISTOPHER
6,633 -2.3%
25.59
US$169,759 		6,633 -2.3% 25.59 US$169,759
2019-04-09 2019-04-05 PlS Planned sale
MACKAY GEOFFREY

See Remarks

Executive Director
13,302 -3.1%
27.26
US$362,618 		13,302 -3.1% 27.26 US$362,618
Explore more

More insider trading research around Tectonic Therapeutic Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America